

Date of last issue: 16.10.2020

according to Regulation (EC) No. 1907/2006

Revision Date:

Ganirelix Formulation

Version

4.5	09.04.2021	22	209-00018	Date of first issue: 15.10.2014				
SE	SECTION 1: Identification of the substance/mixture and of the company/undertaking							
1.1	Product identifier							
	Trade name	:	Ganirelix Formula	ation				
1.2	Relevant identified uses of t Use of the Sub- stance/Mixture	he s :		ure and uses advised against				
1.3	Details of the supplier of the	e sat	ety data sheet					
	Company	:	Organon & Co. 30 Hudson Stree 07302 Jersey Ci	t, 33nd floor ty, New Jersey, U.S.A				
	Telephone	:	551-430-6000					
	E-mail address of person responsible for the SDS	:	EHSSTEWARD@	⊉organon.com				

SDS Number:

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATI	ON ((EC) No 1272/2008)
Reproductive toxicity, Categ	jory	1B H360Fd: May damage fertility. Suspected of dam- aging the unborn child.
Specific target organ toxicity exposure, Category 1	/ - re	epeated H372: Causes damage to organs through pro- longed or repeated exposure.
2.2 Label elements		
Labelling (REGULATION (EC) No 12 Hazard pictograms :		No 1272/2008)
Signal word	:	Danger
Hazard statements	:	H360Fd May damage fertility. Suspected of damaging the unborn child. H372 Causes damage to organs through prolonged or re- peated exposure.
Precautionary statements	:	Prevention:

P201 Obtain special instructions before use.

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020	
4.5	09.04.2021	22209-00018	Date of first issue: 15.10.2014	

P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label: Ganirelix

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.


SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Ganirelix	124904-93-4	Repr. 1B; H360Fd STOT RE 1; H372 (Bone marrow, Liver, Adrenal gland, <u>spleen, Ovary)</u> specific concentration limit Repr. 1B; H360Fd >= 0.01 % STOT RE 1; H372 >= 0.01 %	>= 0.01 - < 0.1

For explanation of abbreviations see section 16.





Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22209-00018	Date of first issue: 15.10.2014

SECTION 4: First aid measures

4.1 Description of first aid measure	S
General advice :	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders :	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled :	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact :	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact :	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed :	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
4.2 Most important symptoms and e	effects, both acute and delayed
Risks :	May damage fertility. Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure.
4.3 Indication of any immediate me	dical attention and special treatment needed

- 4.3 Indication of any immediate medical attention and special treatment needed
 - Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media		
Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.



according to Regulation (EC) No. 1907/2006

Ganirelix Formulation

Versi 4.5	ion	Revision Date: 09.04.2021		S Number: 209-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014
5.2 S	special	hazards arising from	the	substance or mix	xture
	Specific fighting	-	:	Exposure to comb	pustion products may be a hazard to health.
	Hazard ucts	ous combustion prod-	:	No hazardous cor	nbustion products are known
5.3 A	dvice	for firefighters			
	Special for firef	protective equipment ighters	:		e, wear self-contained breathing apparatus. tective equipment.
	Specific ods	c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions	
Environmental precautions	 Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain-	
	ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.	
	Clean up remaining materials from spill with suitable absor- bent.	
	Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable.	
	Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.	

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.



according to Regulation (EC) No. 1907/2006

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22209-00018	Date of first issue: 15.10.2014

SECTION 7: Handling and storage

7.1 Precautions for safe handling **Technical measures** See Engineering measures under EXPOSURE 5 CONTROLS/PERSONAL PROTECTION section. Local/Total ventilation If sufficient ventilation is unavailable, use with local exhaust ventilation. Advice on safe handling Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye Hygiene measures flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 7.2 Conditions for safe storage, including any incompatibilities Requirements for storage Keep in properly labelled containers. Store locked up. Keep areas and containers tightly closed. Store in accordance with the particular national regulations. Do not store with the following product types: Advice on common storage Strong oxidizing agents Organic peroxides **Explosives** Gases 7.3 Specific end use(s) Specific use(s) No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ganirelix	124904-93-	TWA	0.2 µg/m3 (OEB 5)	Internal

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22209-00018	Date of last issue: 16.10.2 Date of first issue: 15.10.2	
	4			
		Wipe limit	2 µg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye protection : Hand protection		Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	No personal respiratory protective equipment normally re- quired.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state Colour Odour Odour Threshold	:	Aqueous solution No data available No data available No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	100 °C
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper	:	No data available

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Ver 4.5	sion	Revision Date: 09.04.2021		S Number: 209-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014
flammability limit					
Lower explosion limit / Lower flammability limit		:	No data available		
	Flash p	point	:	No data available	
	Auto-ig	nition temperature	:	No data available	9
		position temperature omposition tempera-	:	No data available	
	рН		:	5	
	Viscosi Visc	ty cosity, kinematic	:	No data available	
	Solubili Wat	ity(ies) er solubility	:	completely miscil	ble
	Partitio octanol	n coefficient: n-	:	No data available	
		pressure	:	23 hPa (20 °C)	
	Relative	e density	:	1	
	Relative	e vapour density	:	No data available	
		e characteristics ticle size	:	No data available	
9.2		formation			
	Explosi	ves	:	Not explosive	
	Oxidizi	ng properties	:	The substance of	r mixture is not classified as oxidizing.
	Evapor	ation rate	:	No data available	9
	Molecu	lar weight	:	No data available	•

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.


10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid





Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22209-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014
Condi	tions to avoid	: None known.	
	npatible materials		
Mater	ials to avoid	: Oxidizing ager	nts
	rdous decompositio zardous decompositio	n products on products are known	
SECTION	I 11: Toxicological	information	
11.1 Infori	mation on hazard cla	sses as defined in R	egulation (EC) No 1272/2008
Inform expos	nation on likely routes sure	of : Inhalation Skin contact Ingestion Eye contact	
	e toxicity	ilabla information	
	assified based on ava	liable information.	
	oonents:		
		of : LD50 (Rat): 40	mg/kg
Skin	corrosion/irritation		
Not cl	assified based on ava	ilable information.	
	us eye damage/eye i		
	assified based on ava	ilable information.	
Comp	oonents:		
Ganir	-		
Speci Metho		: Rabbit : Draize Test	
Resul	t	: Mild eye irritatio	on
Resp	iratory or skin sensi	tisation	
-	sensitisation assified based on ava	ilable information.	
-	iratory sensitisation assified based on ava	ilable information.	
	oonents:		
Ganir			
Test∃ Speci Resul	Гуре es	: Maximisation T : Guinea pig : negative	est

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

ersion 5	Revision Date: 09.04.2021	SDS Nu 22209-0		Date of last issue: 16.10.2020 Date of first issue: 15.10.2014
	cell mutagenicity			
	assified based on avail	able inforr	nation.	
Comp	oonents:			
Ganir	-	_	_	
Geno	toxicity in vitro	Test		se mutation assay Imonella typhimurium
		Test		rse mutation assay cherichia coli
		Test	Type: in vit system: Ch ult: negative	inese hamster ovary cells
Geno	toxicity in vivo	Spe App	cies: Mouse	ro micronucleus test re: Intravenous
Germ sessn	cell mutagenicity- As- nent		ght of evider mutagen.	nce does not support classification as a ger
	nogenicity assified based on avail	able inforr	nation.	
Repro	oductive toxicity			
May c	lamage fertility. Suspec	ted of dan	naging the u	nborn child.
Comp	oonents:			
Ganir	elix:			
Effect	s on fertility	Spe App Dura Ferti	cies: Rat lication Rout	
		Spe App Dura Ferti	cies: Rat, fe lication Rout ation of Sing ility: LOAEL	e: Subcutaneous le Treatment: 8 Weeks
		Spe App Fert		y e: Subcutaneous : 0.02 mg/kg body weight

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22209-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014
Effects on foetal develop- ment		Species: Rat, Application R Embryo-foeta	nbryo-foetal development female oute: Subcutaneous I toxicity: LOAEL: 10 µg/kg /o-foetal toxicity
		Species: Rab Application R Embryo-foeta	nbryo-foetal development bit, female oute: Subcutaneous I toxicity: LOAEL: 30 µg/kg /o-foetal toxicity
Repro sessr	oductive toxicity - As- nent	ity, based on	e of adverse effects on sexual function and fertil- animal experiments., Some evidence of adverse velopment, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

: Rat

: 0.02 mg/kg

: Subcutaneous : 6 Months

: Bone marrow

: Mouse, female

: 2 mg/kg

Components:

Ganirelix:

Exposure routes	: Ingestion
Target Organs	: Bone marrow, Liver, Adrenal gland, spleen, Ovary
Assessment	: Causes damage to organs through prolonged or repeated
	exposure.

Repeated dose toxicity

Components:

Ganirelix:

Species NOAEL LOAEL Application Route Exposure time Target Organs

Species LOAEL Application Route Expos Targe

LOAEL	:	0.3 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	3 Months
Target Organs	:	Liver, Adrenal gland, spleen, Ovary
Species	:	Mouse, male
LÖAEL	:	3 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	3 Months
Target Organs	:	Liver, Adrenal gland, spleen

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number:Date of last issue: 16.10.202022209-00018Date of first issue: 15.10.2014	
	EL cation Route sure time	 Monkey 2.5 mg/kg Subcutaneous 6 Months No significant adverse effects were reported 	
-	ration toxicity classified based on ava	ble information.	
11.2 Infor	mation on other haza	5	
Endo	ocrine disrupting pro	ties	
<u>Prod</u> Asse	l <mark>uct:</mark> ssment	 The substance/mixture does not contain components ered to have endocrine disrupting properties according REACH Article 57(f) or Commission Delegated regula (EU) 2017/2100 or Commission Regulation (EU) 2018 levels of 0.1% or higher. 	g to tion
Expe	erience with human e	osure	
<u>Com</u>	ponents:		
Gani	relix:		
Inhal	ation	: Symptoms: The most common side effects are:, vagin bleeding, Headache, Abdominal pain, Nausea, ectopic nancy, miscarriage	

SECTION 12: Ecological information

12.1 Toxicity		
Components:		
Ganirelix:		
Ecotoxicology Assessmen	t	
Acute aquatic toxicity	:	No data available
Chronic aquatic toxicity	:	No data available
12.2 Persistence and degradabi No data available	ility	
12.3 Bioaccumulative potential		
No data available		
12.4 Mobility in soil		
No data available		



according to Regulation (EC) No. 1907/2006

Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22209-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014				
	12.5 Results of PBT and vPvB assessment						
Produ	uct:						
Assessment		to be either p very persiste	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.				
12.6 Endocrine disrupting properties							
Prod	uct:						
Assessment :		ered to have	ce/mixture does not contain components consid- endocrine disrupting properties according to cle 57(f) or Commission Delegated regulation				

levels of 0.1% or higher.

(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user Not applicable

14.7 Maritime transport in bulk according to IMO instruments

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22209-00018	Date of first issue: 15.10.2014

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	 Conditions of restriction for the fol- lowing entries should be considered: Number on list 3 Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	: Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	: Not applicable
Regulation (ÉC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	: Not applicable
Seveso III: Directive 2012/18/EU of the European Parlian	nent and of the Council on the control of

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H360Fd	:	May damage fertility. Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated

:	Causes damage to organs through prolonged or repeated
	exposure if swallowed.

Full text of other abbreviations

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version	Revision Date:	SDS Number: 22209-00018	Date of last issue: 16.10.2020
4.5	09.04.2021		Date of first issue: 15.10.2014

Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure


ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Classification of the mixtur	Classification procedure:	
Repr. 1B	H360Fd	Calculation method
STOT RE 1	H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their





Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22209-00018	Date of first issue: 15.10.2014

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN